Targeting Myeloid Cells To Restrict Gamma-herpesvirus Spread
Funder
National Health and Medical Research Council
Funding Amount
$643,152.00
Summary
Gamma-herpesviruses infect most people and cause cancers. Vaccines to date have worked poorly. We have identified a key role for myeloid cells in infection that suggests a new approach. Interferons restrict infection in some myeloid cells. We will test whether inducing interferons can make all myeloid cells restrictive and reduce chronic infection. We will test then whether myeloid-restricting antibodies can recruit the same defences to provide a basis for vaccination.
Mechanisms That Control Epstein Barr Virus Infection And Their Dysregulation In X-linked Lymphoproliferative Disease
Funder
National Health and Medical Research Council
Funding Amount
$453,986.00
Summary
EBV is ubiquitous virus that infects more than 90% of the population worldwide. Although infection is largely asymptomatic in most healthy individuals, EBV is nonetheless associated with the development of at least 7 distinct types of human malignancies. Most importantly, EBV is still a huge healthy problem in conditions of immune suppression. Therefore a better understanding of the mechanisms involved in effective control of the virus will help develop better immune therapies and vaccines.
Multipathogen Adoptive Immunotherapy For Post-transplant Virus-associated Diseases
Funder
National Health and Medical Research Council
Funding Amount
$1,074,188.00
Summary
This project is aiming to develop an “off-the-shelf” killer T cell therapy for transplant patients and patients with virus-associated malignancies. This therapy is based on a novel technology developed by our group which allows rapid expansion of killer T cells directed against multiple viruses.
Immunobilogy Of Human Herpesviruses: From Bench To Bedside
Funder
National Health and Medical Research Council
Funding Amount
$926,980.00
Summary
This Fellowship application is aiming to translate our newly emerging knowledge on immune regulation of human herpesviruses and associated diseases from bench to bedside. We are aiming develop new platform technologies which will allow us to test novel immunotherapeutic strategies to treat herpesvirus-associated diseases.